Weight Loss Treatment
We provide expert care and advice about improving your lifestyle and losing and managing your weight safely.
We offer a range of weight loss options, including prescription treatments such as Mounjaro (Tirzepatide), Wegovy (Semaglutide), Saxenda (Liraglutide), and Orlistat.
What is Mounjaro (Tirzepatide)?
Mounjaro, also known by its active ingredient Tirzepatide, has gained attention recently for its effectiveness in supporting weight loss. Originally launched in the U.S. in 2022 to treat type 2 diabetes, it was later approved in 2023 under the name Zepbound for weight management when combined with a reduced-calorie diet and increased physical activity. Mounjaro is now available in the UK by prescription.
This once-weekly injectable helps control appetite and reduce cravings, and has shown significant results in clinical trials for weight reduction.
How does Mounjaro Work?
Developed by Eli Lilly, Mounjaro is a weekly injection designed to help you feel fuller for longer, reducing your appetite between meals. It is licensed and approved in the UK for weight loss and available only by prescription.
More information about Tirzepatide:
Tirzepatide (marketed as Mounjaro) is a self-administered injection taken once a week. It works by helping you feel less hungry and more satisfied after eating. Your healthcare provider will demonstrate how to use it safely and effectively.
Currently, tirzepatide is only available on the NHS when prescribed through a specialist weight management service.
If your healthcare provider believes it’s the right option for you, they’ll explain how it works, including its benefits, possible side effects, and how to use it properly.
To get the best results, tirzepatide must be combined with a healthy, calorie-controlled diet and regular physical activity.
Important Considerations:
Tirzepatide is not suitable if you are pregnant, planning to become pregnant, breastfeeding, or have specific health conditions.
If you’re on the contraceptive pill, it’s advised to use an additional method—such as condoms—during the first 4 weeks of starting tirzepatide and for 4 weeks after each dosage increase. This is because the effectiveness of the pill may be reduced during these periods.
Eligibility for Tirzepatide on the NHS:
Tirzepatide may be recommended for weight management if you are an adult living with obesity and have at least one weight-related condition, such as type 2 diabetes or high blood pressure.
To qualify for tirzepatide on the NHS, both of the following must apply:
